UNSPSC 51434604: Utibapril

This classification denotes an antihypertensive agent with the molecular formula C22H31N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 87I5H747BC, chemically known as 1,3,4-thiadiazole-2-carboxylic acid, 5-(1,1-dimethylethyl)-3-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-2,3-dihydro-, (2s-(2r*,3(r*(r*))))- but generally known as utibapril, which bears US NIH Compound Identifier 60359.

UNSPSC 51434604 Utibapril, a Commodity code, covers emergency and essential medications supplied to state and local health and rescue agencies. Recent state and local solicitations show procurement bodies acquiring specific branded and generic pharmaceuticals in bulk quantities — epinephrine, labetalol, adenosine, and diltiazem preparations for emergency medical services — as well as generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers to state facilities. Issuing bodies include municipal purchasing departments (City of Tampa), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work entails supply agreements with firm pricing, compliance with Good Manufacturing Practices and Drug Supply Chain Security Act requirements, Safety Data Sheets documentation, and expiration-date and shelf-life guarantees. SLBE and other set-asides appear in municipal solicitations; federal accessibility standards (WCAG 2.2 Level AA, Section 508) are increasingly required.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Bid No. 26-P-00188 for Advanced Life Support Medications, due April 8, 2026, sought four emergency medications totaling approximately $40,000 with a one-year term and renewal options, with a 5 percent SLBE bid discount not to exceed $10,000. The Texas HHS Commission issued an exploratory Request for Information (RFI No. HHS0017013, due April 3, 2026) on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, signaling future formal procurement. MMCAP's Request for Proposal (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to supply state and local facilities across Minnesota and Oregon required vendors to work through three authorized wholesalers and meet 3 percent administrative fee structures, two-year terms, and performance penalties of $200 to $1,500 per violation.